Cargando…
KSI-301: antibody biopolymer conjugate in retinal disorders
KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far hav...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278447/ https://www.ncbi.nlm.nih.gov/pubmed/34291186 http://dx.doi.org/10.1177/25158414211027708 |
_version_ | 1783722262014197760 |
---|---|
author | Chandrasekaran, Priya R. Madanagopalan, V.G. |
author_facet | Chandrasekaran, Priya R. Madanagopalan, V.G. |
author_sort | Chandrasekaran, Priya R. |
collection | PubMed |
description | KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials. |
format | Online Article Text |
id | pubmed-8278447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82784472021-07-20 KSI-301: antibody biopolymer conjugate in retinal disorders Chandrasekaran, Priya R. Madanagopalan, V.G. Ther Adv Ophthalmol Review KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials. SAGE Publications 2021-07-12 /pmc/articles/PMC8278447/ /pubmed/34291186 http://dx.doi.org/10.1177/25158414211027708 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Chandrasekaran, Priya R. Madanagopalan, V.G. KSI-301: antibody biopolymer conjugate in retinal disorders |
title | KSI-301: antibody biopolymer conjugate in retinal disorders |
title_full | KSI-301: antibody biopolymer conjugate in retinal disorders |
title_fullStr | KSI-301: antibody biopolymer conjugate in retinal disorders |
title_full_unstemmed | KSI-301: antibody biopolymer conjugate in retinal disorders |
title_short | KSI-301: antibody biopolymer conjugate in retinal disorders |
title_sort | ksi-301: antibody biopolymer conjugate in retinal disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278447/ https://www.ncbi.nlm.nih.gov/pubmed/34291186 http://dx.doi.org/10.1177/25158414211027708 |
work_keys_str_mv | AT chandrasekaranpriyar ksi301antibodybiopolymerconjugateinretinaldisorders AT madanagopalanvg ksi301antibodybiopolymerconjugateinretinaldisorders |